Page 1

GENFIT TOWARDS BETTER MEDICINE PRESS RELEASE GENFIT : Third Quarter 2021 Financial Information Cash and cash equivalents : € 91.5 million as of September 30 , 2021 Lille , France ; Cambridge , MA ; November 8 , 2021 - GENFIT ( Nasdaq and Euronext : GNFT ) , a late - stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases , today announced its cash position as of September 30 , 2021 and revenues for the first nine months of 20211 . Cash Position As of September 30 , 2021 , the Company's cash and cash equivalents amounted to € 91.5 million compared with € 199.3 million a year earlier . As of June 30 , 2021 , cash and cash equivalents totaled € 104.4 million . As a reminder , GENFIT announced on September 29 , 2021 that given its cash position as of June 30 , 2021 and the payments made to that date , the cost saving plan initiated in the second half of 2020 should allow the Company to reduce its net cash burn to € 120 million for both 2021 and 2022 ( excluding € 47.5 million partial buyback of the OCEANES completed in January 2021 ) . Revenues² Revenues for the first nine months of 2021 amounted to € 20 thousand compared to € 350 thousand for the same period in 2020 . Revenues for the first nine months of 2020 resulted mainly from non - recurring services provided and revenues under the licensing and collaboration agreements signed with Labcorp and Terns Pharmaceuticals . ABOUT GENFIT GENFIT is a late - stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases . GENFIT is a pioneer in the field of nuclear receptor - based drug discovery , with a rich history and strong scientific heritage spanning more than two decades . 1 Unaudited financial information under IFRS 2 Revenue recognized under IFRS 15 GENFIT | 885 Avenue Eugène Avinée , 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1